⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977605 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL15539349 | 0.96 | — | — | |
| SCHEMBL879636 | 0.87 | — | — | |
| SCHEMBL19090363 | 0.84 | — | — | |
| SCHEMBL16877333 | 0.84 | CCR5 (0.47) | — | |
| Hydrochloric Acid SCHEMBL30224904 | 0.84 | — | — | |
| SCHEMBL8542060 | 0.84 | — | — | |
| SCHEMBL4555410 | 0.84 | — | — | |
| SCHEMBL3721399 | 0.84 | — | — | |
| SCHEMBL3721400 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 964 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4688784-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | claimed |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | claimed |
| EP-4648763-A2 | COMPOUNDS FOR FGFRS INHIBITORS | Cogent Biosciences, Inc. (US) | 2025-11-19 | — | — | EP | claimed |
| CN-116120287-B | Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein | 勃林格殷格翰国际有限公司 | 2025-01-28 | — | — | CN | claimed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | claimed |
| US-20240343736-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-10-17 | — | — | US | claimed |
| WO-2024206766-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | claimed |
| WO-2024206747-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | claimed |
| US-20240270741-A1 | COMPOUNDS FOR FGFRS INHIBITORS | COGENT BIOSCIENCES, INC. | 2024-08-15 | — | — | US | claimed |
| US-6028073-A | N-substituted 3-azabicyclo (3.2.0)heptane derivatives useful as neuroleptics | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-22 | — | — | US | claimed |
| US-5753690-A | N-substituted azobicycloheptane derivatives, the preparation and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 1998-05-19 | — | — | US | claimed |
| EP-0647231-B1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS, ETC. | BASF AG (DE) | 1997-08-27 | — | — | EP | claimed |
| EP-0775113-A1 | N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS | BASF AKTIENGESELLSCHAFT (DE) | 1997-05-28 | — | — | EP | claimed |
| US-5616705-A | N-substituted azabicycloheptane derivatives, their preparation and use | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-01 | — | — | US | claimed |
| EP-0646113-B1 | SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATES USEFUL AS INTERMEDIATE PRODUCTS | BASF AG (DE) | 1996-12-18 | — | — | EP | claimed |
| EP-0646110-B1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS | BASF AG (DE) | 1996-10-23 | — | — | EP | claimed |
| US-5521209-A | N-substituted azabicyclo[3.2.0]heptane derivatives as neuroleptics, the preparation and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 1996-05-28 | — | — | US | claimed |
| WO-1996004245-A1 | N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-15 | — | — | WO | claimed |
| US-5475105-A | N-substituted azabicycloheptane derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | claimed |